The costs of at least 350 drugs in the U.S. are expected to rise in 2026, according to a new analysis, despite many of the drugmakers pledging to offer more favorable prices under new Trump administration policies. New data from the health care research firm 3 Axis Advisors, first reported by Reuters, found that a…
